Rapport Net Working Capital from 2010 to 2026

RAPP Stock   27.93  0.04  0.14%   
Rapport Therapeutics Net Working Capital yearly trend continues to be relatively stable with very little volatility. Net Working Capital is likely to drop to about 173.3 M. During the period from 2010 to 2026, Rapport Therapeutics Net Working Capital destribution of quarterly values had range of 316.6 M from its regression line and mean deviation of  75,948,868. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
346.2 M
Current Value
173.3 M
Quarterly Volatility
101.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Rapport Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rapport Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 0.0 or Selling General Administrative of 26.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 13.16. Rapport financial statements analysis is a perfect complement when working with Rapport Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Rapport Stock
Check out the analysis of Rapport Therapeutics Correlation against competitors.
Evaluating Rapport Therapeutics's Net Working Capital across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Rapport Therapeutics Common's fundamental strength.

Latest Rapport Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Rapport Therapeutics Common over the last few years. It is Rapport Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rapport Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Rapport Net Working Capital Regression Statistics

Arithmetic Mean79,263,876
Geometric Mean47,714,409
Coefficient Of Variation128.23
Mean Deviation75,948,868
Median29,605,000
Standard Deviation101,637,363
Sample Variance10330.2T
Range316.6M
R-Value0.68
Mean Square Error5973.5T
R-Squared0.46
Significance0
Slope13,619,534
Total Sum of Squares165282.5T

Rapport Net Working Capital History

2026173.3 M
2025346.2 M
2024301 M
2023142.1 M

About Rapport Therapeutics Financial Statements

Rapport Therapeutics shareholders use historical fundamental indicators, such as Net Working Capital, to determine how well the company is positioned to perform in the future. Although Rapport Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Rapport Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Rapport Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working Capital346.2 M173.3 M

Pair Trading with Rapport Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rapport Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Rapport Stock

  0.76HCM HUTCHMED ChinaPairCorr
  0.52ELVN Enliven TherapeuticsPairCorr
  0.497XP OrganonPairCorr
  0.44NXS Next SciencePairCorr
  0.41BSFA ANI PharmaceuticalsPairCorr
The ability to find closely correlated positions to Rapport Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rapport Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rapport Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rapport Therapeutics Common to buy it.
The correlation of Rapport Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rapport Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rapport Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rapport Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Rapport Stock Analysis

When running Rapport Therapeutics' price analysis, check to measure Rapport Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics is operating at the current time. Most of Rapport Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics' price. Additionally, you may evaluate how the addition of Rapport Therapeutics to your portfolios can decrease your overall portfolio volatility.